Cargando…
Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors
Despite rapid development and deployment of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), clinically relevant modalities to curb the pandemic by directly attacking the virus on a genetic level remain highly desirable and are urgently needed. Here we comprehensively i...
Autores principales: | Becker, Jonas, Stanifer, Megan Lynn, Leist, Sarah Rebecca, Stolp, Bettina, Maiakovska, Olena, West, Ande, Wiedtke, Ellen, Börner, Kathleen, Ghanem, Ali, Ambiel, Ina, Tse, Longping Victor, Fackler, Oliver Till, Baric, Ralph Steven, Boulant, Steeve, Grimm, Dirk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758558/ https://www.ncbi.nlm.nih.gov/pubmed/35038579 http://dx.doi.org/10.1016/j.ymthe.2022.01.024 |
Ejemplares similares
-
AAV-mediated in vivo knockdown of luciferase using combinatorial RNAi and U1i
por: Koornneef, A, et al.
Publicado: (2011) -
Determination of AAV properties by single amino acids: Go(o)d is in the details
por: Maiakovska, Olena, et al.
Publicado: (2022) -
AAV vector-mediated in vivo reprogramming into pluripotency
por: Senís, Elena, et al.
Publicado: (2018) -
Dynamics of Virus-Receptor Interactions in Virus Binding, Signaling, and Endocytosis
por: Boulant, Steeve, et al.
Publicado: (2015) -
Differential Regulation of Type I and Type III Interferon Signaling
por: Stanifer, Megan L., et al.
Publicado: (2019)